A selective TLR8-agonist called moltolimod (APExBio, Houston, TX, USA), also known as VTX-2337, has demonstrated its ability to augment the clinical response of cetuximab (a clinically approved and EGFR-specific monoclonal antibody), in cases of LA or R/M HNSCC [58,59]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.